A detailed history of Black Rock Inc. transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Black Rock Inc. holds 4,436,102 shares of AUTL stock, worth $13.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,436,102
Previous 4,055,920 9.37%
Holding current value
$13.3 Million
Previous $25.9 Million 40.34%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$3.33 - $5.68 $1.27 Million - $2.16 Million
380,182 Added 9.37%
4,436,102 $15.4 Million
Q1 2024

May 10, 2024

BUY
$5.39 - $7.29 $14.6 Million - $19.7 Million
2,700,581 Added 199.26%
4,055,920 $25.9 Million
Q4 2023

Feb 13, 2024

BUY
$2.13 - $6.63 $1.25 Million - $3.9 Million
588,242 Added 76.68%
1,355,339 $8.73 Million
Q3 2023

Nov 13, 2023

SELL
$2.32 - $3.36 $241,041 - $349,093
-103,897 Reduced 11.93%
767,097 $1.79 Million
Q2 2023

Aug 11, 2023

SELL
$1.64 - $3.21 $23,784 - $46,554
-14,503 Reduced 1.64%
870,994 $2.07 Million
Q1 2023

May 12, 2023

BUY
$1.75 - $2.25 $828,182 - $1.06 Million
473,247 Added 114.8%
885,497 $1.63 Million
Q4 2022

Feb 13, 2023

SELL
$1.74 - $3.27 $60,212 - $113,158
-34,605 Reduced 7.74%
412,250 $783,000
Q3 2022

Nov 14, 2022

SELL
$2.04 - $3.76 $42,821 - $78,926
-20,991 Reduced 4.49%
446,855 $956,000
Q2 2022

Aug 12, 2022

BUY
$2.04 - $4.68 $165,509 - $379,697
81,132 Added 20.98%
467,846 $1.33 Million
Q1 2022

May 12, 2022

SELL
$3.52 - $5.46 $299,266 - $464,203
-85,019 Reduced 18.02%
386,714 $1.61 Million
Q4 2021

Feb 10, 2022

BUY
$5.1 - $7.0 $1.64 Million - $2.25 Million
321,761 Added 214.55%
471,733 $2.45 Million
Q3 2021

Nov 09, 2021

BUY
$5.32 - $7.37 $506,096 - $701,115
95,131 Added 173.47%
149,972 $983,000
Q2 2021

Aug 11, 2021

BUY
$4.78 - $7.96 $262,139 - $436,534
54,841 New
54,841 $364,000

Others Institutions Holding AUTL

About Autolus Therapeutics plc


  • Ticker AUTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 90,909,800
  • Market Cap $272M
  • Description
  • Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...
More about AUTL
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.